United BioPharma (UBP, 6471) announced that the company has closed a NT$900 million round of financing, bringing the capital of the company to NT$1760 million.The government fund of MOEA and Cathay Life Insurance Company are among the new investors, each investing NT$48 million and $18 million respectively. Funds will be used to support the clinical trials and pre-clinical studies of the company’s pipeline, including phase III of anti-HIV therapeutic mAb UB-421, phase II of anti-HSV therapeutic mAb UB-621, phase I of anti-Her 2 therapeutic mAb UB-921 and pre-clinical study of anti-IgE therapeutic mAb UB-221.
About United BioPharma (6471)
UBP was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnering with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on the development, manufacture, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs, to improve the health of mankind. For more information, please visit http://www.unitedbiopharma.com
United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.
Victor Run-Ben Sun
Spokesperson and Vice President of Public Affairs